Document Type

Article

Language

eng

Publication Date

11-2012

Publisher

Public Library of Science

Source Publication

PLoS One

Source ISSN

1932-6203

Original Item ID

doi: 10.1371/journal.pone.0047839

Abstract

Glioblastoma Multiforme (GBM) is a tumor with high mortality and no known cure. The dramatic molecular and clinical heterogeneity seen in this tumor has led to attempts to define genetically similar subgroups of GBM with the hope of developing tumor specific therapies targeted to the unique biology within each of these subgroups. Recently, a subset of relatively favorable prognosis GBMs has been identified. These glioma CpG island methylator phenotype, or G-CIMP tumors, have distinct genomic copy number aberrations, DNA methylation patterns, and (mRNA) expression profiles compared to other GBMs. While the standard method for identifying G-CIMP tumors is based on genome-wide DNA methylation data, such data is often not available compared to the more widely available gene expression data. In this study, we have developed and evaluated a method to predict the G-CIMP status of GBM samples based solely on gene expression data.

Comments

Published version. PLoS One, Vol. 7, No. 11 (November, 2011): e47839. DOI. © 2012 Public Library of Science. Used with permission.

Download

Share

COinS